

Maria Gazouli, Biologist, is Professor of Biology – Nanomedicine at the Department of Biology at National & Kapodistrian University of Athens (NKUA), School of Medicine.



She performed her 1st PhD training at the Department of Biology, School of Science of NKUA in partnership with the Hellenic Pasteur Institute, her 2nd PhD training at the Department of Microbiology, School of Medicine of NKUA, and her postdoctoral work in the USA at Cell Biology and Pharmacology Department, Georgetown University Medical Center, Washington DC. From 2000 to 2001 Dr Gazouli was Researcher Fellow at NCSR Demokritos, Institute of Biology and from 2001-2003 was Researcher Fellow at Department of Histology – Embryology, School of Medicine, NKUA.

From 2004-2006, Dr Gazouli was Technical Scientific Staff at the Laboratory of Biology, School of Medicine, NKUA. In 2007 she joined the NKUA Medical School as Lecturer of Biology, in 2012 she was promoted to Assistant Professor of Molecular Biology and in 2016 she promoted to Associate Professor of Molecular Biology. In 2020 she promoted to Professor of Biology – Nanomedicine.

Dr M. Gazouli work refers mainly to molecular basis of diseases mainly autoimmune diseases and cancer, to molecular detection of pathogens and the investigation of the pathogenesis of the diseases they cause to humans. Recently Dr Gazouli was involved in the incorporation of nanotechnology to targeted cancer detection, imaging and drug delivery. She honored with Fulbright Scholarship for the Development of Nanotechnology-based Biosensor Arrays for the Detection of Circulating Colorectal Cancer Cells at University of Maryland, College Park, MD, USA.

Dr Gazouli work is reflected in >240 publications that have received >11000 citations and *h*-index=55 (Google scholar, 1/1/2021). She owns 1 granted International Patent and 3 European Patents. She has given more than 50 invited lectures at international/national conferences, and universities and has trained several junior scientists. She has served as ad hoc reviewer for various scientific journals (e.g. Inflammatory Bowel Disease, Oncology, Molecular Medicine, BMC Cancer, Gene, Journal of Crohn's and Colitis, Scientific Reports, Current Stem Cell Research & Therapy, International Journal of Nanomedicine etc.) and as an expert evaluator for the National Research Grant Funding Agencies of Greece, Broad Medical Research Program Inflammatory Bowel Disease Grants, the National Science Centre (Narodowe Centrum Nauki), Krakow, the PISCOPIA Fellowship Programme on behalf of the University of Padova, Italy, the Czech-Norwegian Research Programme, the Qatar National Research Fund, the Danish Council for Independent Research for DFF – YDUN Research Project, the Italian Ministry of Education (MIUR), University and Research and the Evaluation of research products. She been the scientific coordinator of 2 European Commission-funded collaborative research programmes, 1 European Joint Action on Rare Cancers involving more than 20 research teams across Europe.

Dr Gazouli teaches Biology and Genetics to undergraduate medical students and shas contributed to the translation of biology textbook in Greek. He also teaches various aspects of Molecular Biology in master programmes of NKUA, University of Thessaly, and Democritus University of Thrace. She is coordinator of National and International Research grants (ie Joint Actions, Horizon 2020 etc). Currently she is National Representative at the Committee of Advanced Therapies (CAT) of the European Medicine Association.

ORCID ID: 0000-0002-3295-6811 / Researcher ID: I-2572-2018

Representative Publications

1. Andreou NP, Legaki E, Dovrolis N, Boyanov N, Georgiou K, Gkouskou K, Gazouli M. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Dig Liver Dis. 2020 Dec 15:S1590-8658(20)31051-3.
2. Katifelis H, Mukha I, Bouziotis P, Vityuk N, Tsoukalas C, Lazaris AC, Lyberopoulou A,

Theodoropoulos GE, Efsthathopoulos EP, Gazouli M. Ag/Au Bimetallic Nanoparticles Inhibit Tumor Growth and Prevent Metastasis in a Mouse Model. *Int J Nanomedicine*. 2020 Aug 12;15:6019-6032.

3. Mavragani CP, Nezos A, Dovrolis N, Andreou NP, Legaki E, Sechi LA, Bamias G, Gazouli M. Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota. *Inflamm Bowel Dis*. 2020 Sep 18;26(10):1543-1553

4. Dovrolis N, Michalopoulos G, Theodoropoulos GE, Arvanitidis K, Kolios G, Sechi LA, Eliopoulos AG, Gazouli M. The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases. *Microorganisms*. 2020 Mar 20;8(3):438.

5. Katifelis H, Lyberopoulou A, Mukha I, Vityuk N, Grodzyuk G, Theodoropoulos GE, Efsthathopoulos EP, Gazouli M: Ag/Au bimetallic nanoparticles induce apoptosis in human cancer cell lines via P53, CASPASE-3 and BAX/BCL-2 pathways. *Artif Cells Nanomed Biotechnol*. 2018;46(sup3):S389-S398

6. Tsigaridas A, Anagnostopoulos AK, Papadopoulou A, Ioakeim S, Vaiopoulou A, Papanikolaou IS, Viazis N, Karamanolis G, Mantzaris GJ, Tsangaris GT, Gazouli M: Identification of serum proteome signature of irritable bowel syndrome: Potential utility of the tool for early diagnosis and patient's stratification. *J Proteomics*. 188:167-172, 2018.

7. Legaki E, Roubelakis MG, Theodoropoulos GE, Lazaris A, Kollia A, Karamanolis G, Marinos E, Gazouli M: Therapeutic Potential of Secreted Molecules Derived from Human Amniotic Fluid Mesenchymal Stem/Stroma Cells in a Mice Model of Colitis. *Stem Cell Rev*. 12(5):604-612, 2016.

8. Gazouli M, Wouters MM, Kapur-Pojskić L, Bengtson MB, Friedman E, Nikčević G, Demetriou CA, Mulak A, Santos J, Niesler B: Lessons learned--resolving the enigma of genetic factors in IBS. *Nat Rev Gastroenterol Hepatol*, 13(2):77-87, 2016.

9. Gazouli M, Anagnostopoulos AK, Papadopoulou A, Vaiopoulou A, Papamichael K, Mantzaris G, Theodoropoulos GE, Anagnou NP, Tsangaris GT: Serum protein profile of Crohn's disease treated with infliximab. *J Crohns Colitis*, 7(10):e461-70, 2013.

10. Gazouli M, Zacharatos P, Gorgoulis V, Mantzaris G, Papalambros E, Ikonopoulos J. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. *Gastroenterology* 126(1):367-9, 2004.